What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Heart failure
- Myocardial infarction
William H. Frishman mainly focuses on Internal medicine, Pharmacology, Cardiology, Endocrinology and Anesthesia.
His research related to Disease, Angina, Heart failure, Incidence and Beta-adrenergic blocking agent might be considered part of Internal medicine.
His studies in Angina integrate themes in fields like Placebo, Clinical trial, Ventricular Tachyarrhythmias and Heart rate.
In general Pharmacology, his work in Clinical pharmacology is often linked to Blocking linking many areas of study.
His study brings together the fields of Fibrinogen and Cardiology.
His Anesthesia research includes themes of Artery and Coronary artery bypass surgery.
His most cited work include:
- Development of dementing illnesses in an 80-year-old volunteer cohort. (380 citations)
- Co‐Enzyme Q10: A New Drug for Cardiovascular Disease (190 citations)
- Application of transesophageal echocardiography to continuous intraoperative monitoring of left ventricular performance. (187 citations)
What are the main themes of his work throughout his whole career to date?
William H. Frishman focuses on Internal medicine, Cardiology, Anesthesia, Pharmacology and Blood pressure.
Disease is closely connected to Endocrinology in his research, which is encompassed under the umbrella topic of Internal medicine.
As a part of the same scientific study, he usually deals with the Cardiology, concentrating on Verapamil and frequently concerns with Calcium channel.
His study looks at the intersection of Anesthesia and topics like Placebo with Adverse effect, Combination therapy and Essential hypertension.
His Drug, Pharmacokinetics and Side effect study in the realm of Pharmacology connects with subjects such as Blocking.
The concepts of his Blood pressure study are interwoven with issues in Supine position, Urology and Diuretic.
He most often published in these fields:
- Internal medicine (62.61%)
- Cardiology (43.48%)
- Anesthesia (26.09%)
What were the highlights of his more recent work (between 1994-2018)?
- Internal medicine (62.61%)
- Pharmacology (23.48%)
- Cardiology (43.48%)
In recent papers he was focusing on the following fields of study:
William H. Frishman mostly deals with Internal medicine, Pharmacology, Cardiology, Endocrinology and Disease.
William H. Frishman has researched Pharmacology in several fields, including Chelation therapy, Chemotherapy and Blood pressure.
The study of Cardiology is intertwined with the study of Left ventricular hypertrophy in a number of ways.
His Endocrinology research is multidisciplinary, incorporating elements of Agonist and Receptor.
His research in Disease focuses on subjects like Intensive care medicine, which are connected to Smoking status and Complication.
His studies deal with areas such as Isradipine, Clinical trial, Nifedipine, Placebo and Heart rate as well as Angina.
Between 1994 and 2018, his most popular works were:
- Student research projects and theses: should they be a requirement for medical school graduation? (104 citations)
- Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. (96 citations)
- Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease (83 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Myocardial infarction
William H. Frishman mainly investigates Internal medicine, Pharmacology, Endocrinology, Blood pressure and Anesthesia.
His Internal medicine study incorporates themes from Oncology and Cardiology.
His Cardiology research includes elements of Platelet and Aspirin.
William H. Frishman interconnects Cardioprotective Agent, Heart failure and Clinical pharmacology in the investigation of issues within Endocrinology.
His study in Blood pressure is interdisciplinary in nature, drawing from both Diuretic and Urology.
His Anesthesia research is multidisciplinary, incorporating perspectives in Diuresis, Discontinuation, Nifedipine and Agonist, Fenoldopam.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
